Vrije Universiteit Brussel
Verified
Jette, Belgium
Not recruiting
Study on the Effectiveness of Olaparib for Patients with Advanced Cancers and Specific Genetic Mutations
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effectiveness of a medication called olaparib, also known by its code name AZD-2281, in treating advanced cancers. These cancers are characterized by specific genetic changes, known as mutations, in genes responsible for a process called homologous recombination. Some of these genes include BRCA1, BRCA2, and ATM. The study aims to observe how well olaparib works in patients with these genetic mutations.
Participants in the study will receive olaparib in the form of film-coated tablets, which are taken orally. The study will compare the effects of olaparib on the cancer's response rate and how long the response lasts. The trial will also monitor the safety of the medication by recording any side effects experienced by participants. The study is designed to last up to 24 months, during which participants will have regular check-ups and assessments to track their progress.
The goal of this research is to better understand how olaparib can help treat advanced cancers with specific genetic mutations. By doing so, it hopes to provide more effective treatment options for patients with these types of cancers. The study will also explore how the medication's effectiveness relates to specific genetic changes in the tumors, providing valuable insights into personalized cancer treatment.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
12 criteria
- Provide informed consent before any study-specific procedures.
- Be willing and able to follow the study rules, including treatment, visits, and exams.
- Have at least one tumor that can be measured by a CT scan and checked multiple times.
- A sample of the tumor, preserved in a special way, must be available for genetic testing.
- Be a female or male aged over 18 years.
- Have advanced cancer with a specific genetic change, except for certain breast, prostate, or ovarian cancers.
- No approved targeted therapy available for the specific genetic change in the tumor type.
- No other clinical trial available for the specific genetic change in the tumor type.
- Have normal organ and bone marrow function, checked within 28 days before starting the study treatment.
- Have an ECOG performance status of 0-1, which means being fully active or having some symptoms but nearly fully active.
- Have a life expectancy of at least 16 weeks.
- For women who can have children, be postmenopausal or have a negative pregnancy test within 28 days before starting the study treatment and confirmed on the first day of treatment.
Who cannot join the trial?
4 criteria
- Patients who do not have a **germline mutation** or a **somatic tumor mutation** in specific genes cannot participate. These genes include BRCA1/2, ATM, and others. A **germline mutation** is a genetic change that is present in every cell of the body and can be passed to children. A **somatic tumor mutation** is a genetic change that occurs in a tumor and is not inherited.
- Patients who do not have a mutation in genes that cause **HRD** (Homologous Recombination Deficiency) are excluded. **HRD** is a condition where cells are unable to repair DNA damage properly.
- Patients who are not within the specified age range for the study cannot participate. The study includes certain age categories.
- Patients who are part of a vulnerable population are not eligible. A vulnerable population includes groups who may have limited ability to give informed consent or are at higher risk of harm.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Olaparib is a medication used in this clinical trial to treat advanced cancers in patients who have specific genetic mutations. These mutations are in genes that are involved in repairing damaged DNA. Olaparib works by blocking a protein that helps cancer cells repair their DNA, which can lead to the death of these cancer cells. This medication is being tested to see how well it can shrink tumors and how long it can keep the cancer from getting worse in patients with these genetic mutations.
What is already known about the treatment
Olaparib – Olaparib is a medication administered orally in the form of tablets. It is currently being studied for its effectiveness in treating advanced cancers in patients with specific genetic mutations. The main therapeutic use of Olaparib is for cancers associated with mutations in genes responsible for DNA repair, such as BRCA1 and BRCA2. At the molecular level, Olaparib works by inhibiting an enzyme called PARP, which helps repair damaged DNA in cells. By blocking this enzyme, Olaparib prevents cancer cells from repairing themselves, leading to their death. It is classified as a PARP inhibitor in pharmacology.
Investigated diseases
Advanced Cancer with Homologous Recombination Deficiency (HRD) – This condition involves a group of cancers characterized by the inability of cells to repair DNA damage through the homologous recombination repair pathway. It often occurs due to mutations in specific genes such as BRCA1, BRCA2, and others involved in DNA repair. As the disease progresses, the accumulation of DNA damage can lead to uncontrolled cell growth and tumor development. Patients with HRD-related cancers may experience a variety of symptoms depending on the location and type of cancer. The progression of these cancers can vary widely, with some growing slowly and others more rapidly. Understanding the genetic mutations involved is crucial for studying the disease's behavior and potential responses to treatment.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518522-32-00Protocol codeBSMO 1-2018Estimated enrolment351 patientsSponsorBelgian Society Of Medical Oncology
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?